Dare Bioscience (DARE) Cash from Investing Activities (2013 - 2025)
Dare Bioscience's (DARE) quarterly Cash from Investing Activities came in at -$206641.0 in Q4 2025, up 63.29% YoY from -$126551.1 in Q4 2024, and down 18.28% on a QoQ basis from -$174702.0 in Q3 2025.
Dare Bioscience (DARE) Cash from Investing Activities (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Cash from Investing Activities data on file, last reported at -$206641.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 63.29% year-over-year to -$206641.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$385278.0 (up 32.77% YoY) and the FY2025 annual result came in at -$385278.0, up 32.77% from the prior year.
- Cash from Investing Activities eased to -$206641.0 in Q4 2025, from -$174702.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $282325.0 in Q3 2024 to a low of -$607331.0 in Q4 2023.
- A 5-year average of -$111023.1 and a median of -$22099.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 22418.76% — and 2024, when it jumped 1377.55%.
- Tracing DARE's Cash from Investing Activities over 5 years: stood at -$14524.0 in 2021, then soared by 81.43% to -$2697.0 in 2022, then sank by 22418.76% to -$607331.0 in 2023, then grew by 7.32% to -$562849.0 in 2024, then surged by 63.29% to -$206641.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$206641.0 (Q4 2025), -$174702.0 (Q3 2025), and $153396.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -206,641.00 |
| Dec 31, 2025 | -206,641.00 |
| Sep 30, 2025 | -174,702.00 |
| Sep 30, 2025 | -174,702.00 |
| Jun 30, 2025 | 153,396.00 |
| Jun 30, 2025 | 153,396.00 |
| Mar 31, 2025 | -157,331.00 |
| Mar 31, 2025 | -157,331.00 |
| Dec 31, 2024 | -562,849.00 |
| Dec 31, 2024 | -562,849.00 |
| Sep 30, 2024 | 282,325.00 |
| Sep 30, 2024 | 282,325.00 |
| Jun 30, 2024 | -285,226.00 |
| Jun 30, 2024 | -285,226.00 |
| Mar 31, 2024 | -7,296.00 |
| Mar 31, 2024 | -7,296.00 |
| Dec 31, 2023 | -607,331.00 |
| Dec 31, 2023 | -607,331.00 |
| Sep 30, 2023 | -22,099.00 |
| Sep 30, 2023 | -22,099.00 |